Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Alan L. Rubino
AddedMar 31, 2024
UpdatedMay 1, 2026
Alan L. Rubino

Alan L. Rubino

Co-Founder, New American Therapeutics

Alan L. Rubino's Career

New American Therapeutics
New American Therapeutics

Roseland, NJ, US

Co-Founder
Genisphere
Genisphere

Hatfield, PA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Alan L. Rubino's Career

New American Therapeutics
New American Therapeutics
Series D$53M52010Roseland, NJ, US
Co-Founder

Leadership at New American Therapeutics

Timothy RothwellTimothy RothwellCo-Founder

Similar to New American Therapeutics

NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
Cardurion PharmaceuticalsCardurion PharmaceuticalsBurlington, MA, USTherapeuticsest. 2017Cardurion PharmaceuticalsBurlington, MA, US · est. 2017

Boston-based biotech firm specializing in next-gen therapeutics for heart diseases.

Series B · $343.1M42
CortriaCortriaBoston, MA, USMedicines, Pharmaceuticalsest. 2005CortriaBoston, MA, US · est. 2005

Cortria Corp: A US-based pharmaceutical company specializing in cardiovascular disease treatments.

Public · $1.8M1
TheracosTheracosMarlborough, MA, USPharmaceuticalsest. 2000TheracosMarlborough, MA, US · est. 2000

US-based Theracos, Inc. is a pharmaceutical R&D firm, developing novel therapies for unmet medical needs since 2000.

Private Equity · $118.1M75
Genisphere
Genisphere
Series A$6M91997Hatfield, PA, US
Board Member· Board

Leadership at Genisphere

Tom BlissTom BlissCEO
Brian P McVeighBrian P McVeighBoard Member
James KadushinJames KadushinFounder

Similar to Genisphere

NanotransferNanotransferSunnyvale, CA, USDrug Deliveryest. 2021NanotransferSunnyvale, CA, US · est. 2021

Nanotransfer develops versatile, safe, and cost-effective nanoparticle delivery systems for gene therapies, enhancing cellular internalization and specificity.

Pre-Seed · $200k4
Nanoscope TechnologiesNanoscope TechnologiesBedford, TX, USDiagnostics, Therapeuticsest. 2009Nanoscope TechnologiesBedford, TX, US · est. 2009

Nanoscope Technologies: Innovating scientific and biomedical solutions since 2009.

Series A · $4M18
Advanced NanoTherapiesAdvanced NanoTherapiesLos Gatos, CA, USDrug Delivery, Nanoparticlesest. 2018Advanced NanoTherapiesLos Gatos, CA, US · est. 2018

Developing biodegradable nanoparticles to enhance drug uptake and retention for medical devices.

Series A · $16.5M12

Alan L. Rubino's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Alan L. Rubino

Martijn KleijwegtMartijn KleijwegtCo-Founder · LSP BioventuresAlan W. DuntonAlan W. DuntonBoard Member · OragenicsJ Kevin BuchiJ Kevin BuchiBoard Member · Benitec BiopharmaSteve SimpsonSteve SimpsonBoard Member · AmericanPharma TechnologiesPeter B. ArnoldPeter B. ArnoldBoard Member · KeytradeMichael DavidsonMichael DavidsonCo-Founder & Executive Chairman · SonoThera